$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION | 01 Apr 2019 |
| TOTAL VOTING RIGHTS | 01 Apr 2019 |
| AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL | 29 Mar 2019 |
| RESULTS OF PLACING | 29 Mar 2019 |
| FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES | 27 Mar 2019 |
| FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES | 25 Mar 2019 |
| US FDA GRANTS SARACATINIB ODD FOR IPF | 18 Mar 2019 |
| 6-K | 14 Mar 2019 |
| NOTICE OF AGM | 14 Mar 2019 |
| DIRECTOR/PDMR SHAREHOLDING | 12 Mar 2019 |
| FILING OF FORM 20-F WITH SEC | 06 Mar 2019 |
| ANNUAL FINANCIAL REPORT | 05 Mar 2019 |
| TOTAL VOTING RIGHTS | 01 Mar 2019 |
| LYNPARZA RECEIVES POSITIVE EU CHMP OPINION | 01 Mar 2019 |
| LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION | 26 Feb 2019 |
| BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT | 25 Feb 2019 |
| ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS | 14 Feb 2019 |
| US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION | 06 Feb 2019 |
| EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 | 05 Feb 2019 |
| US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION | 05 Feb 2019 |
